

CURRICULUM VITAE

Name	Lerch Erika
Place of Birth	Oberwil b. B., BE 1 son (*2004)
1986 - 12/1992	Study of Human Medicine at the University of Bern
01.01.1993 - 02.28.1994	Pathology Institute of the University of Bern
16.05.1994 - 09.30.1995	Surgical Emergency Department, Clinic Sonnenhof, Berne
01.10.1995 - 31.03.1996	Dissertation, Department of Allergology, Zieglerspital, Bern
04.01.1996 - 06.30.1998	Department of Internal medicine, Kantonsspital, Luzern
07.01.1998 - 06.30.1999	Medical Oncology, Kantonsspital, Luzern
15.10.1999 - 28.02.2000	General practitioner representation, Luzern
01.04.2000 - 03.31.2001	Department of Radio-oncology, Ospedale San Giovanni, Bellinzona
01.04.2001 - 31.03.2002	Department of Medical Oncology and Hematology IOSI, Ospedale San Giovanni, 6500 Bellinzona
1.04.2002 to 14.02.2003	Medical Oncology IOSI, Ospedale La Carita, Locarno
17.02.2003 - 31.12.2003	Department of Hematology + stem cell transplantation University Hospital Basel
01.07.2004 - 30.09.2004	Medical Oncology IOSI, Ospedale San Giovanni, Bellinzona
01.10.2004 - 03.31.2005	Medical Oncology IOSI , Ospedale La Carita, Locarno
01.04.05 - ongoing	Medical Oncology IOSI , Ospedale San Giovanni, Bellinzona

Specific responsibilities:

Since 01.04.2005 Clinical Coordinator Transplant Unit IOSI and responsible for multiple myeloma and other plasma cell disorders within IOSI

Publication list

1. Duration of venom immunotherapy. Lerch E, Muller UR
J Allergy Clin Immunol. 1997 Feb;99(2):271-
2. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
Lerch E, Muller UR
J Allergy Clin Immunol. 1998 May;101(5):606-12.
3. Epilepsia peruviana Schweiz Med Wochenschr. 1998 Oct 10;128(41):1559.
Lerch E, Gossi B, Henzen C.
4. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000 Feb 12;355(9203):542-5.
Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA
5. Acute myeloid leukaemia in Southern Switzerland: a population based analysis. EHA 2005 poster presentation, abstract 445.
Lerch E, Espeli V, Zucca E, Ghielmini M, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F
6. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab
Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, Marone C, Cavalli F.
Eur J Haematol. 2006 Dec;77(6):527-9
7. BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees.
Ponti G, Venesio T, Losi L, Pellacani G, Bertario L, Sala P, Pedroni M, Petti C, Maffei S, Varesco L, Lerch E, Baggio A, Bassoli S, Longo C, Seidenari S. J Invest Dermatol. 2007 Jun;127(6):1387-91.
8. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function.
Siano M, Lerch E, Negretti L, Zucca E, Rodriguez-Abreu D, Oberson M, Leoncini L, Mora O, Sessa C, Gallino A, Ghielmini M. Clin Cancer Res. 2008 Dec 1;14(23):7935-9
9. Prognosis of acute myeloid leukemia in the general population: data from southern Switzerland.
Lerch E, Espeli V, Zucca E, Leoncini L, Scali G, Mora O, Bordoni A, Cavalli F, Ghielmini M.
Tumori. 2009 May-Jun;95(3):303-10
10. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Taverna C, Bargetzi M, Betticher D, Gmür J, Gregor M, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Renner C. Swiss Med Wkly. 2010 May 10.
11. A case of lenalidomide-induced hypersensitivity pneumonitis.
Lerch E, Györök S, Feilchenfeldt J, Mazzucchelli L, Quadri F. Onkologie. 2010;33(5):249-52.
12. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Wannesson L, Bargetzi M, Cairoli A, Cerutti A, Heim D, Hess U, **Lerch E**, Pabst T, Renner C, Samaras P, Zucca E. Leuk Lymphoma. 2013 Jan;54(1):36-40.
13. Y⁹⁰-Ibritumomab tiuxetan (Y⁹⁰-IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).
Voegeli M, Rondeau S, Berardi Vilei S, **Lerch E**, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M.
Hematol Oncol. 2016 Sep 28. doi: 10.1002/hon.2348.
14. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Samaras P, Bargetzi M, Betticher DC, Duchosal MA, Heim D, Hess U, Ketterer N, **Lerch E**, Matthes T, Mey U, Pabst T, Taverna C, Zander T, Renner C. Swiss Med Wkly. 2015 Feb 21;145:w14100. doi: 10.4414/smw.2015.14100.

15. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Gerber B, Manzoni M, Spina V, Brusca A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, **Lerch E**, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. *Haematologica*. 2018 Jun;103(6):e245-e248. doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22. No abstract available
16. Melphalan dose in myeloma patients ≥ 65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Ghilardi G, Pabst T, Jeker B, Müller R, Cairoli A, Müller AMS, Bargetzi M, Hitz F, Baldomero H, Heim D, Schmidt A, Rossi D, Ghielmini M, Wannesson L, **Lerch E**, Samaras P, Schanz U, Passweg JR, Stussi G, Kleber M, Gerber B; Swiss Blood Stem Cell Transplantation Registry. *Bone Marrow Transplant*. 2019 Jul;54(7):1029-1037. doi: 10.1038/s41409-018-0379-y. Epub 2018 Nov
17. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Samaras P, Bargetzi M, Betticher DC, Driessen C, Duchosal MA, Heim D, Ketterer N, **Lerch E**, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C. *Swiss Med Wkly*. 2019 Apr 3;149:w20031. doi: 10.4414/smw.2019.20031. eCollection 2019 Mar 25
18. Daratumumab for Relapsed or Refractory AL Amyloidosis with high Plasma Cell Burden. Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, **Lerch E**, Flammer A, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stussi G, Ghilardi G, Gerber B. *Hematol Oncol*. 2019 Sep 5. doi: 10.1002/hon.2677. [Epub ahead of print]